World

India Gave One Crore HPV Doses in Nine Months. The Last 13% Is Harder.

India has administered more than one crore doses of the human papillomavirus vaccine to 14-year-old girls in under nine months, covering nearly 87% of the identified annual target, the Union Health Ministry said on 21 November. The campaign, launched by Prime Minister Narendra Modi in February 2026, provides free, voluntary, single-dose vaccination at designated government health facilities with parental consent.

One crore doses in nine months is a serious delivery achievement. It is not the same as eliminating cervical cancer. The gap between those two statements is where the next phase of India’s programme will be won or lost.

What the Numbers Show

The annual target cohort is about 1.2 crore girls, based on Registrar General of India 2021 population estimates. According to the Health Ministry figures reported by ET Government and The New Indian Express, six states have reached 100% coverage of their identified target populations: Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar.

Other reported coverage levels include Assam at 95.63%, Telangana at 95.28%, Karnataka at 93.16% and Uttarakhand at 90.17%. Chhattisgarh and Rajasthan have crossed 80% at 86.21% and 85.23%. Kerala is at 77.02%, Tamil Nadu 76.12%, Odisha 74.90% and Dadra and Nagar Haveli and Daman and Diu 72.99%.

The absolute numbers tell a slightly different story. Uttar Pradesh leads with more than 29.33 lakh girls vaccinated, followed by Bihar with over 13.70 lakh and Gujarat with more than 7.75 lakh. Large states can have both high absolute coverage and lower percentage coverage because their eligible cohorts are so big. That distinction matters when states are compared on a leaderboard.

Why Cervical Cancer Is the Real Target

The vaccine is a means, not the end. Cervical cancer is described in the reporting as India’s second most common cancer, and India accounts for about a quarter of global cervical cancer deaths. More than 80,000 cases were reported in 2023-24. India has endorsed the World Health Organisation’s global strategy to eliminate cervical cancer, including the 90-70-90 targets for 2030.

Those targets are not only about vaccination. They also include screening and treatment. A campaign that reaches 90% of girls with the vaccine but neglects screening of adult women will reduce future risk while leaving current patients behind. India already has experience with this problem: our reporting on India’s cancer drug price cuts showed how access improves on paper while treatment systems struggle to deliver.

Single Dose Is an Operational Choice

India’s decision to use a single dose is central to the programme’s speed. It reduces the number of school and facility visits, lowers follow-up requirements and makes consent easier for parents. The Health Ministry notes that more than 800 million HPV vaccine doses have been given globally and that nearly two decades of research and real-world experience support protection against vaccine-targeted infections and precancerous conditions.

All sessions are conducted at designated government facilities under trained medical officers, with 24×7 arrangements for assessing and managing rare adverse events. Paediatricians, gynaecologists and specialists from institutions such as AIIMS have been involved in addressing safety concerns. That trust-building work is as important as the cold chain.

A crore doses is a delivery achievement. Eliminating cervical cancer also needs the less photogenic screening target.

The Last 13% Is Harder

The remaining share of the cohort is likely to be harder to reach: girls out of school, families in remote or mobile communities, and households where consent has been difficult to secure. Some better-off states are also below the national average, which suggests that income and infrastructure alone do not produce full coverage.

This is the familiar last-mile problem in public health. The first 80% can often be reached through schools, routine systems and administrative momentum. The final 20% requires outreach, repeated conversations, accurate micro-planning and locally trusted messengers. It is slower and more expensive per child, and it is exactly where universal programmes prove whether they are universal.

The U-WIN digital platform is being used for real-time monitoring, beneficiary tracking, digital records, slot booking and certificates. Officials say it can identify eligible girls who are still uncovered and help with planning. That is useful only if the data is current and if frontline workers have the time and authority to act on it.

A Model for the Global South, but Not a Copy-Paste One

India’s campaign will be watched across the Global South because it combines a large adolescent cohort, a single-dose protocol, public funding and digital tracking. If the remaining gaps close, the programme will offer a practical template for other middle-income countries facing similar cervical cancer burdens.

But the transferable lesson is not simply “use one dose”. It is that vaccine delivery, reliable registries, community trust and screening have to be funded as one system. Countries that copy the dose without building the registry and the follow-up will get a launch photograph, not a health outcome.

What to Watch

Four indicators matter over the next year. First, whether national coverage moves past 87% and how quickly. Second, whether low-coverage districts are identified and resourced rather than merely named. Third, whether U-WIN data is audited for duplication and misses. Fourth, whether HPV vaccination is linked to a credible cervical cancer screening schedule for adult women.

The sixth state to reach 100%, the highest absolute count and the largest percentage are all useful numbers. The more decisive number will be the one that shows how many girls remain unreachable and what it takes to reach them.

What It Means

India’s HPV campaign has crossed an important threshold. One crore doses in nine months shows that a large, voluntary adolescent vaccination programme can be delivered at scale when the Centre, states, schools and health workers align.

The next test is less glamorous and more important: finish the cohort, keep the records honest, and connect vaccination to screening and treatment. A vaccine can prevent a future case. A health system has to care for the patients who are already here.

Also read: India cut cancer drug prices by up to 96%. The hard part comes next and India’s states are spending ₹4 lakh crore on cash transfers.

Sources: ET Government / PTI, The New Indian Express, The Hindu, Union Health Ministry figures announced 21 November 2026.

Ganesh Kumar R

Ganesh Kumar R writes and edits The Crescent World, with a focus on India's economy, technology and its place in a multipolar world.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button